Start the conversation
Forest Laboratories Inc. (NYSE: FRX)shares soared 65% in the first half of 2014. Sending shares of the biotech company climbing was news that Irish drugmaker Actavis Plc. (NYSE: ACT) agreed to buy N.Y.-based FRX for$25 billion in cash and stock, or $89.48 a share. That was a 25% premium to FRX's closing price prior to the announcement.